ARCHIVES

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

House Approves Additional Funds For NIH and FDA.

June 20, 2008

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

April 25, 2014

Contract Awards Sole Source Negotiations

January 13, 1978

Many Colorectal Cancer Survivors Do Not Receive Recommended Follow-up Care

September 26, 2008

Wake Forest, Norris Cotton Recognized Broder: Oncologists Need a Major Success In The 1990s

August 31, 1990

Tykerb Plus Letrozole Delayed Metastatic Breast Cancer

January 30, 2009